• Facebook
    Twitter
    LInkedIn
    YouTube
    Weibo


Investment, Private Equity

SDIC Leads $39M Round In Chinese Small Interfering RNA Drug Developer Ribo

Follow China Money Network on Facebook, Twitter and LinkedIn.

An advanced manufacture industrial investment fund under China’s SDIC Fund Management Co. has led a RMB270 million (US$39 million) series B round in Suzhou Ribo Life Science Co. Ltd, a small interfering RNA (siRNA) drug developer.

Legend Capital, GGV Capital, China Resources, and a number of RMB funds also participated in the round, according to a company announcement.

Founded in 2007, Ribo develops siRNA therapy for hepatitis B, Hyperlipidaemia and liver cancer.

It formed a strategic partnership with a RNA interference company Quark Pharmaceuticals Inc. and established a joint venture Kunshan RiboQuark Pharmaceutical Science and Technology Co. Ltd in 2012, to focus on clinical research and development in siRNA pharmaceutical.

RiboQuark’s product QPI-1007, an anti Non-Arteritic Anterior Ischemic Optic Neuropathy siRNA Drug, was approved by CFDA in 2015.

Ribo previously raised RMB125 million (US$18 million) series A round from a number of investors including Legend Capital, GGV Capital and Legend Star.

Established in 2009, SDIC Fund manages over RMB50 billion (US$7.2 billion) in assets.

Last December, the firm led a RMB500 million (US$72 million) round in a Jiangsu province-based biopharmaceutical company Ascentage Pharma, as well as a RMB515 million (US$75 million) round in Beijing-based commercial genomic services provider Novogene Technology.





Related News










Leave a Reply

Your email address will not be published. Required fields are marked *